Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Oral semaglutide formulation comparison in healthy participants
NCT05784402Phase 1Completed
- Sponsor
- Novo Nordisk
- Start
- Mar 2023
- Primary completion
- Feb 2024
- Modality
- Peptides, Recombinant Proteins and Enzymes
- Countries
- 2
01
Overview
Phase 1, randomised, open-label trial of semaglutide (4 arms), sponsored by Novo Nordisk. Primary endpoint: Area Under the Semaglutide Plasma Concentration-Time Curve During a Dosing Interval at Steady State at day 147. Started Mar 2023; status: completed.
02
Drugs
Beyond the preview
Go deeper on NCT05784402.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05784402.